Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, Sator, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909071/
https://www.ncbi.nlm.nih.gov/pubmed/36777399
http://dx.doi.org/10.1177/20406223231152785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909071/
https://www.ncbi.nlm.nih.gov/pubmed/36777399
http://dx.doi.org/10.1177/20406223231152785

Ejemplares similares